Remove 2019 Remove Clinical Trials Remove Programs Remove Safety
article thumbnail

GW Pharmaceuticals Pre-Announces Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales

Cannabis Law Report

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Commence clinical program in PTSD.

article thumbnail

Weekly Legislative Roundup 1/4/19

NORML

Happy New Year and welcome to the first Weekly Legislative Roundup of 2019! Steve Cohen (D-TN) and Don Young (R-AK) re-introduced the Compassionate Access, Research Expansion and Respect States (CARERS) Act, which protects those engaged in state-lawful medical marijuana programs from federal prosecution.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Harvard Is Launching America’s First Psychedelics Law and Policy Center

SpeedWeed

The Project on Psychedelics Law and Regulation (POPLAR) is a three-year project aiming to “promote safety, innovation, and equity in psychedelics research, commerce, and therapeutics,” the university said in a press release. Several prestigious American universities have launched their own psychedelics centers in the past decade.

Policy 52
article thumbnail

Senators Call For Report On State Of Psychedelic Research

Cannabis Law Report

In May 2019, Denver became the first city to decriminalize psilocybin, followed by Oakland, CA, Washington, D.C., In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] Clinical Trials and Human Subject Protections. 5, 2019), [link]. [9] Recent Regulatory Developments.

article thumbnail

New Frontiers in the Law of Psychedelics

Cannabis Law Report

Denver, Colorado was the first jurisdiction to decriminalize the use of psilocybin via ballot initiative in May 2019. Then, in November 2019, the FDA granted the designation to the nonprofit Usona Institute to study psilocybin’s effect on major depressive order, for which clinical trials are currently under way.

Law 105
article thumbnail

Is cannabis legal in Australia?

The Cannigma

Australia has a legal medical marijuana program, and while recreational cannabis remains illegal on the federal level, the enforcement of cannabis laws and the penalties handed out can differ widely from one territory to another. This also means that the TGA has not accessed these medicines for their safety, quality, or effectiveness.

article thumbnail

Here’s what you need to know about cannabis research

The Cannigma

However, a result can be statistically significant but not clinically significant–meaning that even though a study may detect a difference on paper, it may make no tangible difference in real-world application. Non-clinical research can help answer questions regarding safety and risk in very powerful ways.